Teva Pharmaceutical Industries Ltd (TEVA) Given Average Rating of “Hold” by Brokerages

Share on StockTwits

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) has been given a consensus recommendation of “Hold” by the twenty-four brokerages that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $20.53.

A number of research analysts recently issued reports on the stock. HSBC set a $12.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “sell” rating in a research note on Tuesday, February 5th. Maxim Group reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Thursday, February 14th. Credit Suisse Group decreased their price target on shares of Teva Pharmaceutical Industries from $26.00 to $20.00 and set a “neutral” rating for the company in a research note on Thursday, February 14th. UBS Group assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Thursday, March 7th. They issued a “buy” rating and a $22.00 price target for the company. Finally, SunTrust Banks assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Tuesday, March 19th. They issued a “hold” rating and a $17.00 price target for the company.

Shares of NYSE TEVA traded down $0.07 during midday trading on Friday, hitting $10.97. The company’s stock had a trading volume of 322,216 shares, compared to its average volume of 15,635,198. The company has a debt-to-equity ratio of 1.66, a quick ratio of 0.62 and a current ratio of 0.96. Teva Pharmaceutical Industries has a 1 year low of $11.26 and a 1 year high of $25.96. The firm has a market cap of $11.17 billion, a price-to-earnings ratio of 3.91, a PEG ratio of 1.49 and a beta of 1.30.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.57 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The business had revenue of $4.30 billion during the quarter, compared to analyst estimates of $4.38 billion. During the same quarter last year, the firm posted $0.94 earnings per share. The business’s revenue for the quarter was down 15.2% compared to the same quarter last year. Equities analysts predict that Teva Pharmaceutical Industries will post 2.26 EPS for the current fiscal year.

In other news, VP Richard Daniell sold 2,098 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $16.88, for a total transaction of $35,414.24. Following the completion of the sale, the vice president now owns 2,098 shares in the company, valued at approximately $35,414.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Deborah A. Griffin sold 4,107 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $16.88, for a total transaction of $69,326.16. Following the sale, the insider now owns 2,941 shares of the company’s stock, valued at approximately $49,644.08. The disclosure for this sale can be found here. Insiders have sold a total of 28,349 shares of company stock valued at $384,241 in the last 90 days. Insiders own 0.49% of the company’s stock.

Large investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. increased its position in Teva Pharmaceutical Industries by 4.0% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 19,861 shares of the company’s stock worth $311,000 after purchasing an additional 767 shares in the last quarter. ARK Investment Management LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 3.6% during the 1st quarter. ARK Investment Management LLC now owns 24,462 shares of the company’s stock valued at $384,000 after buying an additional 856 shares during the last quarter. Hancock Whitney Corp lifted its holdings in shares of Teva Pharmaceutical Industries by 7.8% during the 4th quarter. Hancock Whitney Corp now owns 12,056 shares of the company’s stock valued at $186,000 after buying an additional 868 shares during the last quarter. Financial Counselors Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 0.7% during the 4th quarter. Financial Counselors Inc. now owns 124,805 shares of the company’s stock valued at $1,924,000 after buying an additional 872 shares during the last quarter. Finally, Hartford Investment Management Co. lifted its holdings in shares of Teva Pharmaceutical Industries by 3.1% during the 4th quarter. Hartford Investment Management Co. now owns 29,581 shares of the company’s stock valued at $456,000 after buying an additional 902 shares during the last quarter. Institutional investors and hedge funds own 64.19% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Further Reading: What is net income?

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Contrasting Nexstar Media Group  & FOX
Contrasting Nexstar Media Group & FOX
Contrasting Superior Industries International  and Adomani
Contrasting Superior Industries International and Adomani
Renasant  & Sierra Bancorp  Head-To-Head Review
Renasant & Sierra Bancorp Head-To-Head Review
Reviewing Beyond Meat  and Campbell Soup
Reviewing Beyond Meat and Campbell Soup
Insider Buying: Total Energy Services Inc  Insider Acquires 5,000 Shares of Stock
Insider Buying: Total Energy Services Inc Insider Acquires 5,000 Shares of Stock
Head to Head Analysis: Alta Mesa Resources  and Infrastructure and Energy Alternatives
Head to Head Analysis: Alta Mesa Resources and Infrastructure and Energy Alternatives


© 2006-2019 Ticker Report